Starling Oncology, Inc. - Common Stock, par value $0.0001 per share (STLN)

Q: What does CUSIP 68236X100 represent in this 13F holders report?

CUSIP 68236X100 is the security identifier for STLN - Starling Oncology, Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held STLN - Starling Oncology, Inc. - Common Stock, par value $0.0001 per share in Q3 2025?

107 institutional investors reported STLN - Starling Oncology, Inc. - Common Stock, par value $0.0001 per share for Q3 2025. Use the holders table for investor-level position and value details.

CUSIP: 68236X100

Q3 2025 13F Holders as of 30 Sep 2025

Security type / class: Equity / Common Stock, par value $0.0001 per share
Total 13F shares: 34,670,910
Total 13F value: $120,993,806
Share change: +2,727,316
Put/Call ratio: 6%
SEC-reported price per share: $3.49
Number of holders: 107
Value change: +$10,399,257
Number of buys: 66
Number of sells: 30
Shares outstanding: 101,268,340

Security key

68236X100

Report period

Q3 2025

Institutions

107

Top holders

STLN full security history Ownership snapshot Full 13F holder table Newer quarter: Q3 2026 Starling Oncology, Inc. SEC filings Starling Oncology, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP 68236X100

Newer quarter: Q3 2026

Recent filing periods:

Q3 2026

Ownership snapshot

Top reported holders of STLN - Starling Oncology, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Ravi Yang Sarin

Disclosed value leader

Ravi Yang Sarin

Comparable rows

1/15

Latest evidence

12 Aug 2025

13D/G 3/4/5 13F Lead comparable stake: 4.7% 14 rows are not safely comparable across share classes. 13D/G row: Ravi Yang Sarin Showing 1-6 of 15 holder rows.

Quick read

Ravi Yang Sarin leads the comparable SEC ownership view at 4.7%.

1 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Ravi Yang Sarin's linked filing trail.

Comparable ownership Top 1

Ravi Yang Sarin 4.7%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Ravi Yang Sarin	13D/G 3/4/5 Ravi Sarin · Director 13D/G 3/4/5	4.7% Reported 13D/G · 26 Mar 2025	$11,959,434 4,109,771 shares	$0	26 Mar 2025
James E. Flynn	3/4/5 Possible Members of 10% Group, 10%+ Owner 3/4/5	— mixed-class rows	$448,270 7,887,160 shares mixed-class rows	—	12 Nov 2021
Havencrest Healthcare Partners, L.P.	3/4/5 10%+ Owner 3/4/5	— denominator unverified	$115,652 252,626 shares	—	16 Aug 2024
DFP Sponsor LLC	3/4/5 Possible Members of 10% Group, 10%+ Owner 3/4/5	— mixed-class rows	$5 3,177,583 shares mixed-class rows	—	12 Nov 2021
Richy Agajanian	3/4/5 10%+ Owner 3/4/5	— denominator unverified	— 296,075 shares	—	10 Jun 2022
VANGUARD GROUP INC	13F Company 13F	— denominator unverified	$8,775,819 4,280,887 shares	—	30 Jun 2025

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

107

34,670,910

Rows available

107

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 holders

Q3 2025 holders

107

Holder diff

Investor	Q2 2025 Shares	Q3 2025 Shares	Share Diff	Share Chg %	Q2 2025 value	Q3 2025 value	Value change	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend